nitroxoline has been researched along with nelfinavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
| Liu, JO; Shim, JS | 1 |
| Cama, A; De Lellis, L; De Tursi, M; di Sebastiano, P; Florio, R; Lanuti, P; Marchisio, M; Massucci, A; Natoli, C; Tinari, N; Veschi, S | 1 |
1 review(s) available for nitroxoline and nelfinavir
| Article | Year |
|---|---|
Recent advances in drug repositioning for the discovery of new anticancer drugs.
Topics: Antineoplastic Agents; Computational Biology; Digoxin; Drug Repositioning; Itraconazole; Nelfinavir; Nitroquinolines | 2014 |
2 other study(ies) available for nitroxoline and nelfinavir
| Article | Year |
|---|---|
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Humans; Nelfinavir; Nitroquinolines; Pancreatic Neoplasms | 2018 |